Press Releases

News Brief

Samsung Biologics to attend 2025 BIO International Convention

Samsung Biologics to attend 2025 BIO International Convention image


Samsung Biologics will be attending the 2025 BIO International Convention in Boston between June 16-19 this year.


Stop by Booth #565 to hear how our expanded capabilities and advanced platform technologies can support your program’s success. From monoclonal antibodies (mAbs) and recombinant proteins to complex modalities such as mRNAs, multispecifics, and antibody-drug conjugates (ADCs), our team is ready to support your program’s accelerated path to the next milestone.


The company opened the latest Plant 5 early this year to launch its second Bio Campus, bringing total combined capacity up to 784 kL. With the recent launch of our dedicated ADC facility and our fully integrated, end-to-end offerings, we are uniquely positioned to streamline development and manufacturing.


Samsung Biologics will also showcase its competitive strengths in seamless end-to-end CDMO capabilities to support diverse and complex molecules. In the booth, AI-powered operations and digital transformation to optimize bioprocesses will also be featured.


Meetings with existing and potential clients will take place throughout the event to support them in achieving development and manufacturing milestones.

Samsung Biologics to attend 2025 BIO International Convention image


Samsung Biologics will be attending the 2025 BIO International Convention in Boston between June 16-19 this year.


Stop by Booth #565 to hear how our expanded capabilities and advanced platform technologies can support your program’s success. From monoclonal antibodies (mAbs) and recombinant proteins to complex modalities such as mRNAs, multispecifics, and antibody-drug conjugates (ADCs), our team is ready to support your program’s accelerated path to the next milestone.


The company opened the latest Plant 5 early this year to launch its second Bio Campus, bringing total combined capacity up to 784 kL. With the recent launch of our dedicated ADC facility and our fully integrated, end-to-end offerings, we are uniquely positioned to streamline development and manufacturing.


Samsung Biologics will also showcase its competitive strengths in seamless end-to-end CDMO capabilities to support diverse and complex molecules. In the booth, AI-powered operations and digital transformation to optimize bioprocesses will also be featured.


Meetings with existing and potential clients will take place throughout the event to support them in achieving development and manufacturing milestones.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION